

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM560351

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	Intellectual Property Security Agreement
<b>SEQUENCE:</b>	1

## CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
Bausch Health Ireland Limited		02/04/2020	Limited: IRELAND
Solta Medical, Inc.		02/04/2020	Corporation: DELAWARE

## RECEIVING PARTY DATA

<b>Name:</b>	Barclays Bank PLC, as Collateral Agent
<b>Street Address:</b>	745 Seventh Avenue
<b>City:</b>	New York
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	10019
<b>Entity Type:</b>	PLC: ENGLAND

## PROPERTY NUMBERS Total: 32

Property Type	Number	Word Mark
Serial Number:	88645756	ENVIVE
Serial Number:	88703514	DELBRI
Serial Number:	88703495	ELIREZE
Serial Number:	88712915	THE TOOL BEHIND THE TALENT
Registration Number:	5493221	LIPOSONIX SIMPLIFY
Registration Number:	4543305	VASER
Registration Number:	4356670	LIPOSONIX
Registration Number:	4360403	INTELLIGENT OPTICAL TRACKING
Registration Number:	4570078	CUSTOM CONTOURING
Registration Number:	4572825	VASERSMOOTH
Registration Number:	4498613	VASERSHAPE
Registration Number:	4225719	ORIGINS
Registration Number:	4172439	1 TREATMENT 1 HOUR 1 SIZE SMALLER
Registration Number:	4036170	TOUCHVIEW
Registration Number:	4007549	POWERX
Registration Number:	4007547	VASER IT
Registration Number:	3259488	FRAXEL

OP \$815.00 88645756

Property Type	Number	Word Mark
Registration Number:	2995303	
Registration Number:	2974491	FRAXEL
Registration Number:	3518039	FRAXEL
Registration Number:	3518038	
Registration Number:	3450499	FRAXEL REPAIR
Registration Number:	3561791	FRAXEL RE:STORE
Registration Number:	3625085	VASERLIPO
Registration Number:	3625077	VASERLIPO
Registration Number:	3687904	VASER HI DEF
Registration Number:	3687903	VASER HI DEF
Registration Number:	3113453	VENTX
Registration Number:	3000098	LIPOSELECTION
Registration Number:	2896037	LIPOSONIX
Registration Number:	2636287	SCIENCE TO SURGERY
Registration Number:	2441470	VASER

**CORRESPONDENCE DATA**

**Fax Number:** 8004947512  
*Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.*  
**Phone:** 202.370.4750  
**Email:** ipteam@cogencyglobal.com  
**Correspondent Name:** Joanna McCall  
**Address Line 1:** 1025 Vermont Ave NW, Suite 1130  
**Address Line 2:** COGENCY GLOBAL INC.  
**Address Line 4:** Washington, D.C. 20005

<b>ATTORNEY DOCKET NUMBER:</b>	1183100
<b>NAME OF SUBMITTER:</b>	Ashley Min Joo Kim
<b>SIGNATURE:</b>	/Ashley Min Joo Kim/
<b>DATE SIGNED:</b>	02/04/2020

**Total Attachments: 10**  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page3.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page4.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page5.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page6.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page7.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page8.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page9.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page10.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page11.tif  
source=Q4 Trademark Security Agreement (Barclays) w Cover#page12.tif

## INTELLECTUAL PROPERTY SECURITY AGREEMENT

This INTELLECTUAL PROPERTY SECURITY AGREEMENT is entered into as of February 4, 2020, (this “**Agreement**”), among the entities identified as grantors on the signature pages hereto (collectively, the “**Grantors**”) and Barclays Bank PLC (“**Barclays**”), as collateral agent (in such capacity, the “**Collateral Agent**”) for the Secured Parties.

Reference is made to that certain Third Amended and Restated Pledge and Security Agreement, dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified from time to time and in effect on the date hereof, the “**Security Agreement**”), among the Loan Parties party thereto and the Collateral Agent. The Lenders (as defined below) have extended credit to the Borrowers subject to the terms and conditions set forth in that certain Fourth Amended and Restated Credit and Guaranty Agreement dated as of June 1, 2018 (as amended, restated, amended and restated, supplemented or otherwise modified and in effect on the date hereof, the “**Credit Agreement**”), by and among Bausch Health Companies, Inc. (formerly known as Valeant Pharmaceuticals International, Inc., the “**Parent**”), Bausch Health Americas, Inc. (formerly known as Valeant Pharmaceuticals International, and, together with the Parent, the “**Borrowers**”), certain subsidiaries of the Parent, as subsidiary guarantors, the Lenders from time to time party thereto (the “**Lenders**”), and Barclays, in its capacities as the Swingline Lender and as Administrative Agent for the Lenders. Consistent with the requirements set forth in Sections 4.01 and 5.12 of the Credit Agreement and Section 4.3 of the Security Agreement, the parties hereto agree as follows:

SECTION 1. **Terms.** Capitalized terms used in this Agreement and not otherwise defined herein have the meanings specified in the Security Agreement.

SECTION 2. **Grant of Security Interest.** As security for the prompt and complete payment or performance, as the case may be, in full of the Secured Obligations, each Grantor, pursuant to the Security Agreement, did and hereby does pledge, collaterally assign, mortgage, transfer and grant to the Collateral Agent, its successors and permitted assigns, on behalf of and for the ratable benefit of the Secured Parties, a continuing security interest in all of its right, title or interest in, to or under all of the following assets, whether now owned or at any time hereafter acquired by or arising in favor of such Grantor and regardless of where located (the Trademark Collateral, Patent Collateral and Copyright Collateral, each as defined below, collectively, the “**IP Collateral**”):

A. The “**Trademark Collateral**”, defined as set forth in paragraphs (1) through (4) directly below:

1. all Trademarks, including those Trademark registrations and registration applications in the United States Patent and Trademark Office listed on Schedule I hereto;
2. all goodwill associated with or symbolized by the Trademarks;
3. the right to sue third parties for past, present and future infringements, dilutions or violations of any Trademark; and
4. all proceeds of and rights associated with the foregoing;

B. The “**Patent Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Patents, including those Patent registrations and pending applications in the United States Patent and Trademark Office listed on Schedule II hereto;

2. the right to sue third parties for past, present and future infringements of any Patent; and
3. all proceeds of and any right associated with the foregoing; and

C. The “**Copyright Collateral**”, defined as set forth in paragraphs (1) through (3) directly below:

1. all Copyrights, including those Copyright registrations and pending applications for registration in the United States Copyright Office listed on Schedule III;
2. the right to sue third parties for past, present and future infringements of any Copyright, and
3. all proceeds of and rights associated with the foregoing;

Notwithstanding anything to the contrary in (A) through (C) above, this Agreement shall not constitute a grant of a security interest in any Excluded Assets, including any “intent-to-use” Trademark applications prior to the filing and acceptance of a “Statement of Use” pursuant to Section 1(d) of the Lanham Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto.

**SECTION 3. Security Agreement.** The security interests granted to the Collateral Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Collateral Agent pursuant to the Security Agreement. Each Grantor hereby acknowledges and affirms that the rights and remedies of the Collateral Agent with respect to the IP Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Security Agreement, the terms of the Security Agreement shall govern.

**SECTION 4. Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of New York.

**SECTION 5. Counterparts.** This Agreement may be executed in one or more counterparts and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed an original, but all such counterparts together shall constitute but one and the same instrument. Delivery of an executed counterpart to this Agreement by facsimile transmission or other electronic transmission (such as .pdf or .tif) shall be effective as delivery of a manually signed counterpart of this Agreement.

[Remainder of page intentionally left blank]

BAUSCH HEALTH IRELAND LIMITED

By:



---

Name: William N. Woodfield  
Title: Director

SOLTA MEDICAL, INC.

By:




---

Name: William N. Woodfield  
Title: Director

BAUSCH & LOMB INCORPORATED

By:



---

Name: William N. Woodfield  
Title: Vice President, Treasurer

DOW PHARMACEUTICAL SCIENCES, INC.

By:




---

Name: William N. Woodfield  
Title: Vice President, Treasurer

SALIX PHARMACEUTICALS, INC.

By:




---

Name: William N. Woodfield  
Title: Vice President, Treasurer

SALIX PHARMACEUTICALS, LTD

By:



---

Name: William N. Woodfield  
Title: Vice President, Treasurer

BAUSCH HEALTH US, LLC

By:



---

Name: William N. Woodfield  
Title: Vice President, Capital Markets, Treasury

SANTARUS, INC.

By:



---

Name: William N. Woodfield  
Title: Vice President, Treasurer

Accepted and Agreed:

**BARCLAYS BANK PLC.**  
as Collateral Agent

By: Robert Walsh  
Name:  
Title: **Robert Walsh**  
**Assistant Vice President**

[Signature Page to IPSA – Barclays]

**TRADEMARK**  
**REEL: 006855 FRAME: 0753**

**Schedule I - Trademark Collateral**

<b>Current Owner on TMO Records</b>	<b>Mark Name</b>	<b>Current Application Number</b>	<b>Current Registration Number</b>
BAUSCH HEALTH IRELAND LIMITED	ENVIVE	88645756	
BAUSCH HEALTH IRELAND LIMITED	DELBRI	88703514	
BAUSCH HEALTH IRELAND LIMITED	ELIREZE	88703495	
SOLTA MEDICAL, INC.	THE TOOL BEHIND THE TALENT	88712915	
SOLTA MEDICAL, INC.	LIPSONIX SIMPLIFY	87357057	5493221
SOLTA MEDICAL, INC.	VASER	86099558	4543305
SOLTA MEDICAL, INC.	LIPSONIX	85633020	4356670
SOLTA MEDICAL, INC.	INTELLIGENT OPTICAL TRACKING	85739520	4360403
SOLTA MEDICAL, INC.	CUSTOM CONTOURING	85626559	4570078
SOLTA MEDICAL, INC.	VASERSMOOTH	85569255	4572825
SOLTA MEDICAL, INC.	VASERSHAPE	85569249	4498613
SOLTA MEDICAL, INC.	ORIGINS	85569245	4225719
SOLTA MEDICAL, INC.	1 TREATMENT 1 HOUR 1 SIZE SMALLER	85204189	4172439
SOLTA MEDICAL, INC.	TOUCHVIEW	85121345	4036170
SOLTA MEDICAL, INC.	POWERX	85121336	4007549
SOLTA MEDICAL, INC.	VASER IT	85121320	4007547
SOLTA MEDICAL, INC.	FRAXEL	78774531	3259488
SOLTA MEDICAL, INC.	DESIGN ONLY	78457709	2995303
SOLTA MEDICAL, INC.	FRAXEL	78364508	2974491
SOLTA MEDICAL, INC.	FRAXEL	77975811	3518039
SOLTA MEDICAL, INC.	DESIGN ONLY	77975810	3518038
SOLTA MEDICAL, INC.	FRAXEL REPAIR	77150163	3450499
SOLTA MEDICAL, INC.	FRAXEL RE:STORE	77150160	3561791
SOLTA MEDICAL, INC.	VASERLIP0	76693482	3625085
SOLTA MEDICAL, INC.	VASERLIP0	76693033	3625077
SOLTA MEDICAL, INC.	VASER HI DEF	76693483	3687904
SOLTA MEDICAL, INC.	VASER HI DEF	76693470	3687903



SOLTA MEDICAL, INC.	VENTX	76599960	3113453
SOLTA MEDICAL, INC.	LIPSELECTION	76594677	3000098
SOLTA MEDICAL, INC.	LIPSONIX	76185377	2896037
SOLTA MEDICAL, INC.	SCIENCE TO SURGERY	75950643	2636287
SOLTA MEDICAL, INC.	VASER	75638383	2441470

**Schedule II – Patent Collateral**

<b>Appl. No.</b>	<b>Publ. No.</b>	<b>Patent No.</b>	<b>Title</b>	<b>Current PTO Owner</b>
62/881836			TOPICAL COMPOSITIONS	BAUSCH HEALTH IRELAND LIMITED
62/898419			COMBINATIONS OF RIFAXIMIN AND CHECKPOINT INHIBITORS FOR THE TREATMENT OF CANCER	BAUSCH HEALTH IRELAND LIMITED
62/898903			METHODS OF TREATING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) USING IL-17RA	BAUSCH HEALTH IRELAND LIMITED
62/903206			GRAFTED POLYMER AND USE THEREOF	BAUSCH & LOMB INCORPORATED
62/904790			RIFAXIMIN LIQUID FORMULATIONS	BAUSCH HEALTH IRELAND LIMITED
16/722715			COMPOSITIONS AND METHODS FOR TREATING DISEASES OF THE NAIL	DOW PHARMACEUTICAL SCIENCES, INC.
16/667300			USE OF METHYLNAL TREXONE TO ATTENUATE TUMOR PROGRESSION	SALIX PHARMACEUTICALS, INC.
16/654226			IBS MICROBIOTA AND USES THEREOF	SALIX PHARMACEUTICALS, INC.
16/604244			METHODS FOR MANUFACTURING PHENOXYETHANOL	BAUSCH HEALTH IRELAND LIMITED
16/575769			METHODS FOR TREATING IRRITABLE BOWEL SYNDROME (IBS)	SALIX PHARMACEUTICALS, INC.
16/561525			METHODS FOR TREATING INFECTION	SALIX PHARMACEUTICALS, LTD
16/556664			PAIN MITIGATION BY MECHANICAL STIMULATION WHEN TREATING TISSUE WITH ELECTROMAGNETIC ENERGY	BAUSCH HEALTH IRELAND LIMITED
16/556701			REDUNDANT TRACES FOR FLEXIBLE CIRCUITS USED IN AN ENERGY DELIVERY DEVICE	BAUSCH HEALTH IRELAND LIMITED
16/556616			METHODS AND APPARATUS FOR PUMPING COOLANT TO AN ENERGY DELIVERY DEVICE	BAUSCH HEALTH IRELAND LIMITED
16/556403			ENCRYPTED MEMORY DEVICE	BAUSCH HEALTH IRELAND LIMITED

Appl. No.	Publ. No.	Patent No.	Title	Current PTO Owner
16/377540			TOPICAL COMPOSITIONS AND METHODS FOR TREATING PSORIASIS	BAUSCH HEALTH US, LLC
16/377126			POLYMERIC EMULSION DELIVERY SYSTEMS	BAUSCH HEALTH IRELAND LIMITED
16/435310			STABILIZED EFINAZONAZOLE FORMULATIONS	BAUSCH HEALTH IRELAND LIMITED
16/393171			ANTIBODY FORMULATIONS	SANTARUS, INC.

None.

**Schedule III - Copyright Collateral**